New Directions
Dear Readers, Your author is en route to Chicago to attend the annual meeting of the American Society of Clinical Oncology. It’s the first time in years I’ll be there, and I’m looking forward to ...
ASCO
On Friends Affected by Cancer, and Environment Oncology
If I could pick a field for future investigation that might lead to insight on cancer’s causes and, ultimately, reduce the cancer burden 30 and 50 years from now, I might choose the tiny, under-funded area of environmental oncology
EMILIA Trial: T-DM1 Appears Helpful in Women with Her2+ Metastatic Breast Cancer
The new agent is a hybrid of an old monoclonal antibody, Herceptin, that’s chemically attached to DM1, a traditional kind of chemotherapy. The preliminary results of this randomized trial are encouraging. …It’s hard to know how this promising, likely expensive, intravenous drug will fit in with others for patients with Her2+ breast cancer.
Quotes on Oncology, Via Forbes, and a Spiraling Helix
Forbes kept a close eye on the annual ASCO meeting in Chicago. On THE MEDICINE SHOW, Forbes’ Matthew Herper provides a précis of a speech by outgoing ASCO President Dr. George Sledge. Here are my ...